When Less is More: Can We Abandon Prophylactic Platelet Transfusion in Dengue Fever?

被引：0

作者：

Kurukularatne, Changa ^{[1
,2
]}

Dimatatac, Frederico ^{[1
,2
]}

Teo, Diana L. T. ^{[3
]}

Lye, David C. ^{[1
,2
,4
]}

Leo, Yee Sin ^{[1
,2
,5
]}

机构：

[1] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore

[2] Communicable Dis Ctr, Singapore, Singapore

[3] Hlth Sci Author, Blood Serv Grp, Singapore, Singapore

[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore

[5] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore

来源：

ANNALS ACADEMY OF MEDICINE SINGAPORE | 2011年 / 40卷 / 12期

关键词：

Thrombocytopenia; Preventitive; Arbovirus; Bleeding; Hemorrhage; BLOOD; HEMORRHAGE; SAFETY; RISK; PREVENTION; THRESHOLD; EFFICACY; ADULTS; TRIAL;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dengue fever (DF) has several hematological manifestations including thrombocytopenia and increased bleeding risk. Prophylactic platelet transfusion-in the absence of major bleeding-is utilized in DF with thrombocytopenia with the intention of preventing hemorrhagic complications. However, prophylactic platelet transfusion in DF is neither standardized nor supported by clinical evidence. We conclude that risks, costs and poor resource utilization associated with prophylactic platelet transfusion in DF far outweigh any potential hematological benefit, and as such, should not constitute routine clinical practice.

引用

页码：539 / 545

页数：7

共 37 条

[1]

[Anonymous], 2019, Dengue Guidelines for Diagnosis, Treatment, Prevention and Control

[2]

[Anonymous], 2011, HIST BLOOD TRANSF AM

[3]

[Anonymous], DENGUE DENGUE HAEMOR

[4] Safety of the blood supply in the United States: Opportunities and controversies [J].

AuBuchon, JP ;

Birkmeyer, JD ;

Busch, MP .

ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) :904-909

[5]

Basha J, 2006, INT J EMERGENCY INTE, V9

[6]

BIRKMEYER JD, 1992, AM J MED, V93, P356, DOI 10.1016/0002-9343(92)90255-A

[7] A COMPARISON OF FILTERED LEUKOCYTE-REDUCED AND CYTOMEGALOVIRUS (CMV) SERONEGATIVE BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CMV INFECTION AFTER MARROW TRANSPLANT [J].

BOWDEN, RA ;

SLICHTER, SJ ;

SAYERS, M ;

WEISDORF, D ;

CAYS, M ;

SCHOCH, G ;

BANAJI, M ;

HAAKE, R ;

WELK, K ;

FISHER, L ;

MCCULLOUGH, J ;

MILLER, W .

BLOOD, 1995, 86 (09) :3598-3603

[8] The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy [J].

Callow, CR ;

Swindell, R ;

Randall, W ;

Chopra, R .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (02) :677-682

[9]

Centers for Disease Control and Prevention, 2004, MMWR-MORBID MORTAL W, V54, P168

[10] Transfusion support to Dengue patients in a hospital based blood transfusion service in north India [J].

Chaudhary, Rajendra ;

Khetan, Dheeraj ;

Sinha, Seema ;

Sinha, Pratul ;

Sonker, Atul ;

Pandey, Prashant ;

Das, Sudipta Sekhar ;

Agarwal, Prashant ;

Ray, Vijaylaxmi .

TRANSFUSION AND APHERESIS SCIENCE, 2006, 35 (03) :239-244

← 1 2 3 4 →